Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis

Abstract

Overall, genetic testing should be offered in most patients with ovarian cancer to identify mutations in HRR genes and determine the population that would be susceptible to poly ADP ribose polymerase (PARP) inhibitors.